Site Selection & Feasibility

CROs have site databases. We have real-time data on where patients are today.

Traditional feasibility studies ask investigators how many patients they see and take the answer at face value — even though investigators consistently overestimate by 40 to 60%. The result: 80% of trials with “validated” feasibility still miss their enrollment timelines.

We start from patient behavior instead. Real-time signals from search, social media, forums, and patient advocacy networks tell you where patients matching your protocol are actively researching treatment right now — not where sites happened to perform well one to three years ago.

What you get

Patient-first site ranking. Sites scored and ranked on patient accessibility and proximity to engaged, high-intent patient populations, not just geography.
Predictive enrollment modeling. Machine learning forecasts of site-level enrollment performance, built on current patient research behavior instead of historical averages.
Protocol pressure-testing. Your inclusion/exclusion criteria checked against what real patients in your indication are actually concerned about and how they make treatment decisions.
Competitive landscape mapping. Which sites and regions are already saturated with competing trials, and which represent genuine open opportunity.
Investigator and KOL intelligence. Established thought leaders by region, and emerging investigators with real patient access who haven’t yet been discovered by the CRO databases everyone else uses.
Executive summary with go/no-go recommendations, delivered as a full report plus a presentation-ready deck.

Larger, multi-country engagements add cross-border benchmarking, cultural and operational intelligence by market, competitive trial-pipeline monitoring, and a strategic roadmapping session to translate the findings into an activation plan.

Why it’s different

	Traditional CRO feasibility	VertisPro
Data basis	Static site databases, 1–3 years old	Real-time patient research behavior
Delivery	8–10 weeks	Weeks, not months
What it answers	Which sites performed well historically	Where engaged, eligible patients are right now
Investigator discovery	Established KOLs already in every CRO’s database	Established KOLs and high-access investigators the databases miss

The distinction: site visits tell you if a site can run your trial. Patient intelligence tells you if it will succeed at enrollment.

Timeline

Single-country engagements: 4 weeks
Multi-country strategic engagements: 4 weeks
Global, 5+ country engagements: 8 weeks

This compares to 8–10 weeks for a traditional multi-country CRO feasibility study.

Who this is for

Small-medium biotech (Series A–C) with limited feasibility budgets
Non-US pharma entering unfamiliar markets, especially first entry into the US, EU, or Asia
Academic sponsors running their first industry-sponsored trial
Sponsors without an established CRO relationship who need a complete feasibility solution without the CRO price tag
Sponsors already working with a CRO who want an independent, data-driven second opinion before committing to site selection

What happens next

This works alongside your CRO, not against it — it’s a validation layer, not a replacement. If you’re heading into site selection or want a second opinion on a CRO’s recommendations, this is built to answer that question in weeks.

See a sample report · Book a call to talk through your trial.

→ How our patient intelligence works